NASDAQ:BIIB

Biogen Stock Insider Trading

Healthcare > Drug Manufacturers - General

Buy BIIB

*Your capital is at risk

$207.94

+1.66 (+0.80%)

At Close: Aug 07, 2026

Biogen Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 61.91. In total, the insiders bought 272.52K and sold 30.25K BIIB shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	61.91
● Buy	272.52K shares
● Sell	30.25K shares
72% Buy Activity Negligible or No Correlation
Sell Signal Low Confidence Aug 04, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 61.91. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Feb 06, 2026 Buy	Restricted Stock Unit M-Exempt	Murphy Nicole Head Of Pharm Ops And Tech	Officer	1 940 Value: $390.3K
Feb 06, 2026 Buy	Restricted Stock Unit M-Exempt	Murphy Nicole Head Of Pharm Ops And Tech	Officer	4 683 Value: $942.1K
Feb 06, 2026 Sell	Common Stock F-InKind	Murphy Nicole Head Of Pharm Ops And Tech	Officer	1 017 Value: $204.6K
Feb 06, 2026 Buy	Common Stock M-Exempt	Murphy Nicole Head Of Pharm Ops And Tech	Officer	2 102 Value: $422.9K
Feb 06, 2026 Buy	Common Stock M-Exempt	Murphy Nicole Head Of Pharm Ops And Tech	Officer	1 940 Value: $390.3K
Feb 06, 2026 Sell	Common Stock F-InKind	Murphy Nicole Head Of Pharm Ops And Tech	Officer	1 408 Value: $283.3K
Feb 06, 2026 Buy	Common Stock M-Exempt	Murphy Nicole Head Of Pharm Ops And Tech	Officer	4 683 Value: $942.1K
Feb 06, 2026 Buy	Restricted Stock Unit M-Exempt	Singhal Priya Head Of Development	Officer	2 217 Value: $446.0K
Feb 06, 2026 Buy	Common Stock M-Exempt	Singhal Priya Head Of Development	Officer	2 217 Value: $446.0K
Feb 06, 2026 Buy	Restricted Stock Unit M-Exempt	Singhal Priya Head Of Development	Officer	4 683 Value: $942.1K
Feb 06, 2026 Sell	Common Stock F-InKind	Singhal Priya Head Of Development	Officer	1 412 Value: $284.1K
Feb 06, 2026 Buy	Restricted Stock Unit M-Exempt	Viehbacher Christopher President And CEO	CEO / President	9 008 Value: $1.81M
Feb 06, 2026 Sell	Common Stock F-InKind	Viehbacher Christopher President And CEO	CEO / President	4 356 Value: $876.3K
Feb 06, 2026 Buy	Common Stock M-Exempt	Viehbacher Christopher President And CEO	CEO / President	9 008 Value: $1.81M
Feb 06, 2026 Sell	Common Stock F-InKind	Viehbacher Christopher President And CEO	CEO / President	6 624 Value: $1.33M
Feb 06, 2026 Buy	Common Stock M-Exempt	Viehbacher Christopher President And CEO	CEO / President	15 453 Value: $3.11M
Feb 06, 2026 Buy	Restricted Stock Unit M-Exempt	Viehbacher Christopher President And CEO	CEO / President	15 453 Value: $3.11M
Feb 06, 2026 Buy	Common Stock M-Exempt	Singhal Priya Head Of Development	Officer	4 683 Value: $942.1K
Feb 06, 2026 Sell	Common Stock F-InKind	Singhal Priya Head Of Development	Officer	1 056 Value: $212.4K
Feb 06, 2026 Sell	Common Stock F-InKind	Murphy Nicole Head Of Pharm Ops And Tech	Officer	914 Value: $183.9K
Feb 06, 2026 Buy	Common Stock M-Exempt	Kramer Robin Chief Financial Officer	C-Suite Officer	3 511 Value: $706.3K
Feb 06, 2026 Buy	Common Stock M-Exempt	Kramer Robin Chief Financial Officer	C-Suite Officer	789 Value: $158.7K
Feb 06, 2026 Sell	Common Stock F-InKind	Kramer Robin Chief Financial Officer	C-Suite Officer	273 Value: $54.9K
Feb 06, 2026 Buy	Restricted Stock Unit M-Exempt	Kramer Robin Chief Financial Officer	C-Suite Officer	3 511 Value: $706.3K
Feb 06, 2026 Buy	Restricted Stock Unit M-Exempt	Kramer Robin Chief Financial Officer	C-Suite Officer	703 Value: $141.4K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT BIOGEN INC.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an ad...

Read Full Profile Here